Domestic and foreign pharmaceutical companies big cattle pile exposure semi-annual report Sichuan people Fu was sold medical insurance directory adjustment started.

Author . . . Cephalospora last week to see point 1. Well-known pharmaceutical companies pile exposure semi-annual report; 2. Sichuan People's Fu Pharmaceutical Co., Ltd. was sold; 3. Tiger Pharmaceuticals bedding into the country's third A-H listed CRO enterprises; 4. This year's health insurance directory adjustment started AstraZenein: China's market grew 14% in the first half of 2020 On July 30, British pharmaceutical giant AstraZenein reported first-half 2020 revenue of $12.629 billion, up 14% year-on-year.
from the performance of new products in emerging markets and oncology.
sales totaled $12,359 million, up 13% year-on-year. In the first half of
, AstraZeneite's cancer products revenue was $5,324 million, up 31% YoY, while cardiovascular, kidney and metabolic (CVRM) product revenue was $2,265 million, up 11% YoY, and respiratory and immunology products revenue was $2,676 million, up 7% YoY.
's global revenue of $6 billion in the second quarter, up 9 percent from a year earlier.
but respiratory and immunology product revenues fell 8 percent, mainly due to the impact of the new coronary pneumonia outbreak on Pumikdubao(Budinid) sales in China.
by product: The main core drivers of tumor products include the non-small cell lung cancer treatment drug Terisha, with sales of $2,016 million, up 45% year-on-year ;PD-L1 mono-anti-Infineon sales of $954 million, up 52 Ovarian cancer treatment drug Liptro sales of $816 million, up 60 percent year-on-year, and other chronic leukemia treatment leukemia, sales of $195 million, and the first three co-partner antibody conjoened drug Enhertu, a joint share of revenue of $36 million.
: Total revenue in the second quarter was $10.9 billion, and K sold $3.4 billion! Mercer recently reported second-quarter 2020 sales of $10.9 billion, down 8% year-on-year, and global sales down 5% excluding foreign exchange.
pharmaceutical business revenue of $9.7 billion, down 7% year-on-year, and excluding the adverse effects of foreign exchange, sales fell 6%.
Most notably, the decline in the company's pharmaceutical business was mainly due to the negative impact of the outbreak on vaccines and hospital emergency care products, as well as the continuing impact of the loss of market exclusive rights for some products, partially offset by strong growth in the oncology business. In
's oncology business, Keytruda's sales rose 29 percent to $3.4 billion, helped by continued strong growth in non-small cell lung cancer adaptation and continued absorption of other conditions, including complementary treatments for melanoma, kidney cell cancer, bladder cancer, head and neck cancer, and microsatellular instability (MSI-H) cancer.
higher co-operative revenue associated with Lynparza and Lenvima also contributed to the growth of the oncology business, reflecting continued market penetration of approved adaptations in the United States, Europe and China.
Hengrui: Five-year revenue growth first fell below 20%, research and development investment against the trend of growth of 25% August 1, Hengrui Pharmaceuticals announced the 2020 semi-annual report, from the total revenue and net profit to see Hengrui still maintain the top position of domestic biopharmaceutical enterprises, but compared with the growth rate of the same period last year, the impact of the new crown epidemic is very prominent. according to the
report, Hengrui Pharma's total revenue in the first half of the year was RMB11,309 million, up 12.79 percent from RMB10,026 million in the same period in the same period in 19 years;
even if half a year to achieve 10 billion revenue, but Hengrui still can not escape the impact of the new crown outbreak. In the first half of
, Hengrui's total revenue increased by 12.79 percent year-on-year, while in the past five years, hengrui Pharmaceutical's total revenue in the 2019 half-yearly report increased by 29.19 percent year-on-year, 22.32 percent year-on-year in 2018, 20.18 percent year-on-year in 2017, 20.35 percent year-on-year in 2016 and 24.95 percent year-on-year in 2015.
can be seen that for five years Hengrui Pharmaceuticals has maintained annual growth of more than 20% in the first half of the year, and has continued to grow since 2017.
that the impact of the new crown outbreak has had a significant impact on The growth of Hengrui.
Pharmaceuticals: Ekdini's first-half sales of 924 million yuan August 5, Beda Pharmaceuticals announced its first-half 2020 results, operating income of 952 million yuan, up 24.9% YoY 2%, net profit attributable to common shareholders of listed companies was RMB144 million, up 64.65 percent YoY, and net profit attributable to shareholders of listed companies after non-recurring gains and losses was RMB141 million, up 87.90 percent YoY.
, Ektini maintained high growth in the first half of the year, with sales of 924 million yuan.
also reported that by the end of the reporting period, Ekdini had benefited more than 250,000 patients with advanced lung cancer, including 1,600 patients who had taken ektenyni for more than five years, with cumulative sales exceeding 8 billion yuan.
Bayer: Revenue from winning varieties fell 74% on August 4th, with Bayer reporting 2020Q2 results, with revenues of EUR 10,054 million, down 6.2%, and cumulative first-half revenue of EUR 22,899 million, down 0.3%.
, the pharmaceutical business was affected by COVID-19 and China's volume-and-volume procurement policy, with revenues of EUR 3,992 million, down 8.8 percent, in the second quarter.
china market, Bayer's diabetes drug Glucoba (Akapo sugar, by sugar) won the bid at a low price of 0.181 yuan per tablet in the second batch of national harvests, a drop of 91.56 percent.
, based on its second-quarter results, reported a 74.2 per cent drop in global sales of just 40 million euros in the second quarter, while cumulative sales in the first half of the year fell 54.4 per cent to 156 million euros.
: second quarter results against the trend growth of 24% Eylea, Dupixent is indispensable! On August 5, Regeneration reported second-quarter 2020 revenue of $1.95 billion, up 24% year-on-year and higher than the previous forecast of $1.74 billion.
GAAP diluted earnings per share (EPS) was $7.61 and non-GAAPEPS was $7.16.
net sales in the U.S. market were $1,114 million ($1.16 billion a year earlier), down 4 percent from a year earlier, but still exceeding expectations.
same period last year, sales of Lucentis, a rival product, fell 25 per cent.
Eylea has outperformed the entire anti-VEGF sector and continues to grow its market share, now accounting for 73% of branded drug sales in the U.S. market.
In fact, Eylea's sales have been picking up since May as medical experts redefined offices and patient numbers, and its 12-week flexible interval is a valuable feature of treating patients during a pandemic.
sales of the anti-inflammatory drug Dupixent reached $945 million (recorded by Sanofi), outpacing the general forecast of 4%, driven mainly by the U.S. market.
anti-PD-1 therapy Libtayo also beat industry expectations, with global sales of $80 million in the second quarter.
, Libtayo significantly extended its total survival compared to chemotherapy in a Phase III clinical trial of a first-line treatment for non-small cell lung cancer.
regenerative meta has been planned to submit a new adaptation application in the United States.
: Second quarter 2020 revenue reached a new high of 66 million August 7, Baiji Shenzhou announced recent business highlights, expected milestones and financial results for the second quarter and first half of 2020. John V. Oyler, founder, chief executive officer and chairman of
, said: "We have come a long way since the second quarter , with three applications approved in China for the listing of the eight new drugs, Baizean ® and Park Hyatt® and eight new drug listing applications in China®, the European Union, Australia and Israel®.
revenue hit a new high of about $66 million in the quarter, driven by the company's commercialization team, mainly from our recently launched independent research and development products.
added: "The company's recent success in completing a registered direct release with net income of approximately US$2.07 billion will significantly accelerate the development of the existing extensive research and development pipeline, further expand our portfolio in the field of oncology and other diseases, and continue to build in-house capacity and operations to serve more patients worldwide."
For the remainder of 2020 and 2021, we look forward to publishing key clinical data and expanding the business opportunities of our products by gaining approval in new adaptive and geographic markets and increasing our commercial phase portfolio to 11.
"Ali Health: Discount fund-raising! How can the Internet medical profit model break through? On August 5, Ali Health announced that it had entered into a placement agreement with placement agents Citi Global Financial Limited and Credit Suisse (Hong Kong) Limited to place a total of 499 million new shares at HK$20.05 per share, representing approximately 3.71 per cent of the enlarged issued share capital.
referred to Ali Health's closing price of HK$21.8 on August 4, the public offering was discounted by about 8.03 per cent.
First Sound Pharmaceuticals: $170 million Introduction of a CDK4/6 Inhibitor Greater China Equity August 3, 2020, North Carolina, USA and Nanjing, China, Clinical Stage Oncology Company G1Therapeutics, Inc. (NASDAQ: GTHX) and China First Sound Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of the injectable CDK4/6 inhibitor Trilaciclib in all regions of Greater China (Chinese mainland, Hong Kong, Macau and Taiwan) after China's rapid transformation into a company dominated by innovation and research and development.
discovered and developed by G1, Trilaciclib is a first-class research therapy designed to improve the prognostication of cancer patients undergoing chemotherapy treatment.
is currently listed in the queue for the Hong Kong stock market, and is expected to be heard soon.
(G1 and BI partnered in the United States and Puerto Rico to sell Trilaciclib).
AstraZenewan and Kantai Bio have entered into an authorized partnership with Kantai Bio for the new crown vaccine AstraZenewan today announced the signing of an exclusive licensing partnership framework agreement with Kantai Bio for the Chinese mainland market to actively promote the development, production, supply and commercialization of astrazenevirus vector AZD1222 in the Chinese mainland market through technology transfer.
, the two sides will continue to explore the possibility of cooperation in other regions and markets.
the move will hopefully bring the world's leading vaccine technology globally to China, benefiting all Chinese soon.
is also AstraZene into the corporate social responsibility, adhere to the "in China, for China" long-term commitment to a strong action.
Sichuan People's Fu Pharmaceutical Co., Ltd. was sold on August 5, People's Fu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "People's Fu Pharmaceuticals") issued an announcement to transfer its 70% stake in Sichuan People's Fu Pharmaceutical Co., Ltd. to Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Heavy Pharmaceutical Group").
It is understood that heavy medicine group is based on pharmaceutical business, pharmaceutical research and development of collaborative development of enterprises, is the central and Chongqing two-level drug medical device fixed-point reserve units, but also operating narcotic drugs and the first class of psychotic drugs national wholesale enterprises.
as of December 31, 2019, Heavy Medicine Group's total assets were RMB248.3276 million, net assets were RMB734,459 million, and operating income was RMB33.84 billion and net profit was RMB930 million in 2019.
And Sichuan People's Fu is a hospital drug pure sales, commercial distribution, medical equipment and equipment supplies sales and other business in one integrated pharmaceutical commercial company, the company under the jurisdiction of more than a dozen holding subsidiaries, basically covering all levels of medical and health institutions in Sichuan Province.
Tyger Pharmaceuticals H-share offering price: HK$100/share raising HK$10.7 billion On August 3, Tagg Pharma announced that it had confirmed that it would be listed on the main board of the Hong Kong Stock Exchange from August 7, 2020, with a final price of HK$100.00/share for overseas listed foreign shares (H-shares).
the 31st of July, the company's subscription for the exhibition had reached $91.25 billion, about 154 times oversubscribed.
it is understood that Tiger Pharma's IPO is expected to issue 107 million new shares, accounting for 12.5% of the total number of shares after the issue, to raise HK$10.7 billion, with Merrill Lynch Far East, Haitong International, CITIC Lyons and CITIC Hong Kong as co-sponsors.
, if successfully listed, will be the largest IPO of an Asian biopharmaceutical company so far this year, and will also be the third CRO company listed in China after pharmaceutical companies Mingkangde and Kanglonghua.
this year's health care directory adjustment started! 7 new types of drugs are proposed! On August 3rd, the State Health Insurance Administration issued the Work Programme for the Adjustment of the National Health Insurance Drug Catalog 2020 (draft for comments) (hereinafter referred to as the "Draft of Opinions"), which is open until August 10, 2020.
The draft opinion clearly states that drugs outside the catalogue of drugs that comply with the provisions of Articles 7 and 8 of the Interim Measures for the Administration of Drug Use for Basic Medical Insurance, and which have one of the following circumstances, may be included in the scope of new drugs to be added to the National Basic Medical Insurance Drug Catalog (hereinafter referred to as the Drug Catalog) in 2020.
1. Medication for respiratory diseases related to new coronary pneumonia.
2. Drugs included in the National Essential Medicines Directory (2018 edition).
3. Include in the list of new drugs in urgent clinical need abroad, encourage the catalog of generic drugs, or encourage research and development of declared children's drugs list, and by December 31, 2019 approved by the State Drug Administration to market drugs.
4. The second batch of state-organized medicines centralized procurement of selected drugs.
5. From 1 January 2015 to 31 December 2019, drugs (including those) approved for listing by the State Drug Administration in accordance with the application procedure for registration of new drugs.